COMMUNIQUÉS West-GlobeNewswire

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
02/04/2026
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of [...]
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
02/04/2026
If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration and early death [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02/04/2026
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
02/04/2026
KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the [...]
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
02/04/2026
New regional partnership strengthens Nanox ’s presence and service support across outpatient imaging settings in Colorado , Wyoming and the western parts of Kansas and Nebraska Agreement aligns with Nanox’s strategy to [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
02/04/2026
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals
02/04/2026
Clinically validated image recognition removes patient guesswork, captures multivariate stool data, and supports earlier, more precise assessment of GI patterns CHICAGO, April 02, 2026 (GLOBE NEWSWIRE) -- Cylinder [...]
Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
02/04/2026
– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure – TUCSON, Ariz., April 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ( [...]
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
02/04/2026
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide [...]
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
02/04/2026
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/ [...]
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 [...]
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
02/04/2026
Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on- [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
New system centralizes at-home DNA testing, biological age assessment, and lab diagnostics into a unified reporting experience ST. PETERSBURG, FL, April 02, 2026 (GLOBE NEWSWIRE) -- MyGevity announced the nationwide [...]
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
02/04/2026
NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrations NTR-1011 displayed a predictable pharmacokinetic ( [...]
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]

Pages